Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG FLEXPEN versus SEMGLEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG FLEXPEN versus SEMGLEE.
NOVOLOG FLEXPEN vs SEMGLEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that lowers blood glucose by binding to insulin receptors, facilitating cellular uptake of glucose, and inhibiting hepatic glucose production.
Long-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake (especially in skeletal muscle and fat) and inhibiting hepatic glucose production via binding to insulin receptors, activating the insulin receptor tyrosine kinase cascade.
Subcutaneous injection; 0.5 to 1.0 unit/kg/day divided into doses at mealtimes; dose individualization based on metabolic needs and blood glucose monitoring.
Subcutaneous injection, 0.2 units/kg/day initially, adjusted based on blood glucose levels. Typical maintenance dose: 0.5-1 unit/kg/day.
None Documented
None Documented
Terminal elimination half-life: 5-7 minutes (free insulin aspart in plasma); clinically, the prolonged action (up to 6 hours) reflects continued absorption from subcutaneous depot, not elimination half-life
18.3 hours; reflects protracted absorption from subcutaneous depot, enabling once-daily dosing
Primarily renal (60-80% as unchanged drug via glomerular filtration and tubular reabsorption); biliary/fecal excretion minimal (<2%)
Renal (30-80% as intact insulin); fecal (negligible)
Category C
Category C
Insulin Analog
Insulin Analog